Multispectral Imaging Analysis of Skin Lesions in Patients with Neurofibromatosis Type 1
-
Published:2023-10-25
Issue:21
Volume:12
Page:6746
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Plorina Emilija V.12ORCID, Saulus Kristine1, Rudzitis Ainars3ORCID, Kiss Norbert4ORCID, Medvecz Márta4ORCID, Linova Tatjana5, Bliznuks Dmitrijs6ORCID, Lihachev Alexey1ORCID, Lihacova Ilze1ORCID
Affiliation:
1. Institute of Atomic Physics and Spectroscopy, University of Latvia, LV-1586 Riga, Latvia 2. LTD Longenesis, Dzirnavu 41A-5, LV-1010 Riga, Latvia 3. Pauls Stradins Clinical University Hospital, Pilsoņu 13, LV-1002 Riga, Latvia 4. Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Maria Str. 41, H-1085 Budapest, Hungary 5. Dermatology Clinic, Health Center 4, Skanstes 50, LV-1013 Riga, Latvia 6. Institute of Smart Computing Technologies, Riga Technical University, Zunda Krastmala 10, LV-1658 Riga, Latvia
Abstract
Neurofibromatosis type 1 (NF1) is a rare disease, affecting around 1 in 3500 individuals in the general population. The rarity of the disease contributes to the scarcity of the available diagnostic and therapeutic approaches. Multispectral imaging is a non-invasive imaging method that shows promise in the diagnosis of various skin diseases. The device utilized for the present study consisted of four sets of narrow-band LEDs, including 526 nm, 663 nm, and 964 nm for diffuse reflectance imaging and 405 nm LEDs, filtered through a 515 nm long-pass filter, for autofluorescence imaging. RGB images were captured using a CMOS camera inside of the device. This paper presents the results of this multispectral skin imaging approach to distinguish the lesions in patients with NF1 from other more common benign skin lesions. The results show that the method provides a potential novel approach to distinguish NF1 lesions from other benign skin lesions.
Funder
European Regional Development Fund project European Social Fund project National Research, Development and Innovation Office of Hungary—NKFIH Semmelweis University, Budapest, Hungary
Reference39 articles.
1. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation;Legius;Genet. Med.,2021 2. Magro, G., Broggi, G., Angelico, G., Puzzo, L., Vecchio, G.M., Virzì, V., Salvatorelli, L., and Ruggieri, M. (2022). Practical approach to histological diagnosis of peripheral nerve sheath tumors: An update. Diagnostics, 12. 3. Lobbous, M., Bernstock, J.D., Coffee, E., Friedman, G.K., Metrock, L.K., Chagoya, G., Elsayed, G., Nakano, I., Hackney, J.R., and Korf, B.R. (2020). An Update on Neurofibromatosis Type 1-Associated Gliomas. Cancers, 12. 4. Malignant peripheral nerve sheath tumours in neurofibromatosis 1;Evans;J. Med. Genet.,2002 5. Santoro, C., Bernardo, P., Coppola, A., Pugliese, U., Cirillo, M., Giugliano, T., Piluso, G., Cinalli, G., Striano, S., and Bravaccio, C. (2018). Seizures in children with neurofibromatosis type 1: Is neurofibromatosis type 1 enough?. Ital. J. Pediatr., 44.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|